Showing results (181-190 of 251) with videos related to

Sort By:
Pageof 26
ESMO Open|October 18, 2023
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II studyS Joris, H Denys, J Collignon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorinJ Cassidy, C Twelves, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 13, 2014
Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013D Papamichael, R A Audisio, B Glimelius, et al.
ESMO Open|June 2, 2022
Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRCS Kopetz, A Grothey, E Van Cutsem, et al.
ESMO Open|May 9, 2026
Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2S Joris, H Denys, J Collignon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2016
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinomaS-E Al-Batran, E Van Cutsem, S C Oh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancerM Peeters, T J Price, A Cervantes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative GroupU Vanhoefer, P Rougier, H Wilke, et al.
British Journal of Cancer|September 24, 2014
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL studyE Van Cutsem, C-P Li, E Nowara, et al.
British Journal of Cancer|January 26, 2013
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patientsV Martin, L Landi, F Molinari, et al.
Pageof 26